Comparison · NCT00103844-c17e2f99
Dasatinib vs Imatinib: Number of Participants With Major Cytogenetic Response (MCyR) at Week 12
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dasatinib vs Imatinib: Number of Participants With Major Cytogenetic Response (MCyR) at Week 12. Trial comparisons, record NCT00103844-c17e2f99. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00103844-c17e2f99
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.356 | 0.27 | 0.454 | wilson | |
| Risk in group 2 | 0.286 | 0.178 | 0.424 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0707 | -0.0925 | 0.215 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.25 | 0.746 | 2.09 | log | |
| Odds ratio, group 1 over group 2 | 1.38 | 0.66 | 2.91 | log | |
| Number needed to treat, for one more participant with the outcome on Dasatinib than on Imatinib | 14.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dasatinib | Dasatinib 70 mg twice a day (BID) | 36 | 101 | OG000 |
| Group 2 | Imatinib | Imatinib 400 mg BID | 14 | 49 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Major Cytogenetic Response (MCyR) at Week 12
- Description
Cytogenetic response was based on the prevalence of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as Complete CyR (CCyR; 0% Ph+ cells in metaphase in bone marrow) or Partial CyR (PCyR; \>0% to 35% Ph+ cells in metaphase in bone marrow).
- Time frame
- Week 12
- Population
- All randomized subjects
Source ClinicalTrials.gov
Trial
- Title
- Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
- NCT number
- NCT00103844
- Phases
- PHASE2
- Conditions
- Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
- Interventions
- Dasatinib, Imatinib
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2010-01-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00103844?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00103844-c17e2f99